Gw Research Limited

Institut National De La Sante Et De La Recherche Medicale

Universitë De Bordeaux

Inserm (institut National De La Sante Et De La Recherche Medicale)

Jazz Pharmaceuticals Research UK Limited

Aelis Farma

Inserm

Rafael Maldonado

Geoffrey W Guy

Stephen Wright

Marie Woolley-Roberts

James Brodie

Daniela Parolaro

Livio Luongo

Pier Vincenzo Piazza

Jean-Michel Revest

Monique Vallee

Giovanni Marsicano

Daniela Cota

Francois-Xavier Felpin

Umberto Spampinato

Sergio Vitiello

Luigi Bellocchio

Mathilde Metna

Stéphanie Monlezun

Joanna Neill

Sandy Fabre

François-Xavier Felpin

Aline Marighetto

Andrés Ozaita

Pier-Vincenzo Piazza

Andres Ozaita

Stephanie Monlezun

Harpreet Singh

The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). CBDA has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS and AS. The CBDA is preferably substantially pure. It may take the form of a highly purified extract ofsuch that the CBDA is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDA is synthetically produced.

Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders

The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract ofsuch that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.

Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia

The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.

Antagonists of CB1 receptor

Growing community of inventors

Barcelona, Spain

Rafael Maldonado